Safety Reporting

Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.

 

4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.

The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.

The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.

4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.

4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).

Clinical Research News

Eine Spritze gegen Arthrose? Wissenschaftler berichten über Gelenkreparatur bei Tieren in wenigen Wochen
Pfizer prüft neuen Pneumokokken-Impfstoff für Kinder, die eine Catch-up-Impfung benötigen
Tuberkulose-Behandlung ist ein langer Marathon. Eine neue Studie prüft, ob sie auf 17 Wochen verkürzt werden kann
Nach der Diagnose Typ-1-Diabetes beginnt der Wettlauf gegen die Zeit. Eine neue Studie versucht, das körpereigene Insulin zu erhalten
Wie niedrig sollte das „schlechte“ Cholesterin sein? Studie testet neues Ziel für Hochrisikopatienten
DYNE-251 wird in einer Phase-3-Studie bei Patienten mit Duchenne-Muskeldystrophie getestet
Orales GLP-1 wird bei Menschen mit Typ-2-Diabetes getestet, die während des Ramadan fasten

Bevorstehende klinische Studien

Clinical Research Jobs

More jobs

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren